Straits Times Index
3,324.76 +10.62 (+0.32%) Nikkei
39,173.15 +368.50 (+0.95%) Hang Seng
18,007.71 -20.00 (-0.11%) FTSE 100
8,281.55 +43.83 (+0.53%) Bitcoin USD
61,129.96 -1,220.87 (-1.96%) CMC Crypto 200
1,266.89 +17.77 (+1.42%)
APLS Jan 2026 35.000 put
| Previous close | 8.11 |
| Open | 8.27 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 35.00 |
| Expiry date | 2026-01-16 |
| Day's range | 8.11 - 8.30 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week
While Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shareholders are probably generally happy, the stock hasn't had...
ZacksApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
GlobeNewswireSYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE® (pegcetacoplan injection) preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These positive data from the GALE long-term ext
